Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia

NCT02644655 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Recurrent B-Cell Tumor
Refractory B-Cell Tumor

Interventions

BIOLOGICAL: CD19-specific chimeric antigen receptor

Sponsor

Second Military Medical University